Article
A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.
PloS one - 1 Jan 2013
Trucco Matteo M, Awad Ola, Wilky Breelyn A, Goldstein Seth D, Huang Ruili, Walker Robert L, Shah Preeti, Katuri Varalakshmi, Gul Naheed, Zhu Yuelin J, McCarthy Edward F, Paz-Priel Ido, Meltzer Paul S, Austin Christopher P, Xia Menghang, Loeb David M
Abstract excerpt
Chordoma is a rare primary bone malignancy that arises in the skull base, spine and sacrum and originates from remnants of the notochord. These tumors are typically resistant to conventional chemotherapy, and to date there are no FDA-approved agents to treat chordoma. The lack of in vivo models of chordoma has impeded the development of new therapies for this tumor. Primary tumor from a sacral chordoma was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.